Mehta Vimal bought BTAI
July 22, 2025 · Form 4 insider transaction
Mehta Vimal bought 15,625 shares of BioXcel Therapeutics, Inc., a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 0 days after the transaction.
Footnotes
The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through July 22, 2025 (the "PSUs"). On July 22, 2025, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 15,625 PSUs had been satisfied and 15,625 shares of common stock became issuable to the Reporting Person on July 22, 2025.